Search
Asenapine
go.drugbank.com/drugs/DB06216ApprovedInvestigationalIt is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009. … Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with
Categories: Cytochrome P-450 Substrates, Adrenergic alpha-1 Receptor AntagonistsHydroxyzine
go.drugbank.com/drugs/DB00557ApprovedInvestigational[L9677] The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect. … Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.
Mixtures: DOLMARAL®Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesSelumetinib
go.drugbank.com/drugs/DB11689ApprovedInvestigationalNF-1 is considered rare, with an estimated incidence of 1/3000 individuals. … [A193608] It is a genetic, autosomal dominant condition resulting from mutations of the NF1 gene, which can lead to various complications, including the development of multiple tumours in the nervous system
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesEntacapone
go.drugbank.com/drugs/DB00494ApprovedInvestigationalEntacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. … of levodopa and a decarboxylase inhibitor.
Synonyms: N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide, (E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamideMixtures: LEVO C/E BETA100/25/200, LEVO C/E BETA100/25/200Miltefosine
go.drugbank.com/drugs/DB09031ApprovedInvestigationalMiltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent. … It can be administered topically or orally and is only indicated in patients aged 12 years or older.
Synonyms: hexadecyl 2-(trimethylazaniumyl)ethyl phosphateCategories: P-glycoprotein substratesParamethadione
go.drugbank.com/drugs/DB00617ApprovedParamethadione is an anticonvulsant in the oxazolidinedione class. It is associated with fetal trimethadione syndrome, which is also known as paramethadione syndrome.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesPomalidomide
go.drugbank.com/drugs/DB08910ApprovedInvestigationalPomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexProducts: POMALYST® 4 MG, POMALYST ® 1 MGFusidic acid
go.drugbank.com/drugs/DB02703ApprovedInvestigationalAn antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis.
Mixtures: FUCIDIN H %2 + %1 KREM, 30 G, FUCICORT 20 MG/G + 1 MG/G KREM, 30 GCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsNecitumumab
go.drugbank.com/drugs/DB09559ApprovedInvestigationalWithdrawnNecitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. … Binding of necitumumab to EGFR induces receptor internalization and degradation, thereby preventing further activation of EGFR which is beneficial in NSCLC as many patients have increased protein expression
Rabies immune globulin, human
go.drugbank.com/drugs/DB11603ApprovedIf IMOGAM Rabies Pasteurized is not administered as recommended at the initiation of the post-exposure rabies vaccine series, it can be administered up to eight days following the first dose of the rabies … Recommendations for passive and/or active immunization after exposure to an animal suspected of having rabies have been outlined by the National Advisory Committee on Immunization (NACI), the Advisory
Products: Hyperrab S/d, BERIRAB(R) P